BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220412
DTEND;VALUE=DATE:20220415
DTSTAMP:20260613T061830
CREATED:20211103T060835Z
LAST-MODIFIED:20220103T193734Z
UID:2355-1649721600-1649980799@thebiocalendar.com
SUMMARY:SynBioBeta: Global Synthetic Biology Conference
DESCRIPTION:Live and in person *NEW DATES*: APRIL 12-14\, 2022 @ the Oakland Marriott City Center. \nAfter TWO years of digital meetings\, we’re bringing synthetic biology’s leading community of innovators\, investors\, engineers\,… \nBecause Being in the Same Room is Better Than Being on the Same Zoom\, and we really miss you!
URL:https://thebiocalendar.com/event/synbiobeta-global-synthetic-biology-conference/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220412T000000
DTEND;TZID=UTC:20220414T235900
DTSTAMP:20260613T061830
CREATED:20220212T014934Z
LAST-MODIFIED:20220212T015437Z
UID:2600-1649721600-1649980740@thebiocalendar.com
SUMMARY:Promotional Review Committee Compliance and Best  Practices Summit (PRC) East
DESCRIPTION:The Fierce Promotional Review Committee Compliance and Best Practices Summit will allow cross-functional professionals involved in promotional review boards across large pharma and biotech organizations to learn how to collaborate more effectively and ensure quicker reviews of advertising materials\, while staying compliant.
URL:https://thebiocalendar.com/event/promotional-review-committee-compliance-and-best-practices-summit-prc-east/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/02/PRC22_300x250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220412T000000
DTEND;TZID=UTC:20220414T235900
DTSTAMP:20260613T061830
CREATED:20220212T015234Z
LAST-MODIFIED:20220212T015308Z
UID:2602-1649721600-1649980740@thebiocalendar.com
SUMMARY:MASS East
DESCRIPTION:The Fierce Medical Affairs Strategic Summit is an educational community that provides a holistic view of medical affairs\, allowing organizations to develop a unified scientific voice. Join us and interact with medical affairs colleagues as we tackle different stages of the product lifecycle\, from evidence generation to Phase 4 studies\, to ensure both internal and external messaging are being communicated effectively to thought leaders\, through increased and compliant medical communication strategies.
URL:https://thebiocalendar.com/event/mass-east/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/02/MASS22_300x250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220418
DTEND;VALUE=DATE:20220422
DTSTAMP:20260613T061830
CREATED:20211106T202047Z
LAST-MODIFIED:20220121T085724Z
UID:2372-1650240000-1650585599@thebiocalendar.com
SUMMARY:Drug Discovery Chemistry
DESCRIPTION:Focused on discovery and optimization challenges of small molecule drug candidates\, Drug Discovery Chemistry is a dynamic in-person and online event for medicinal and biophysical chemists working in pharma\, biotech\, and academia. Nearly 800 attendees participated virtually this year\, with 71% of delegates from pharma/biotech and 16% from academia. 60% of attendees were scientists/technologists and 22% were executives/directors. \nSpeakers from the following have already confirmed their participation for April’s event\, which will be available in-person to vaccinated attendees only: Amgen\, Astex Pharmaceuticals\, AstraZeneca\, Aurigene Discovery Technologies\, Bayer Pharmaceuticals\, Baylor College of Medicine\, Biogen\, Bristol Myers Squibb\, Dana Farber Cancer Institute\, ETH Zurich\, Fred Hutchinson Cancer Research Center\, Genentech\, Insilico Medicine\, Merck\, Novartis\, Pfizer\, Progenra\, Scripps Research Institute\, St. Jude Children’s Research Hospital\, and many more. \nLimited speaking opportunities are available. If you would like to be considered for a podium presentation\, please submit a speaker proposal ASAP. As a reminder\, attendees still have on-demand access to watch presentations\, listen to Q&A panel discussions\, review posters\, and much more.
URL:https://thebiocalendar.com/event/drug-discovery-chemistry/
CATEGORIES:Featured
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/11/dch22-conf-header-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220419T190000
DTEND;TZID=UTC:20220419T213000
DTSTAMP:20260613T061830
CREATED:20220413T184929Z
LAST-MODIFIED:20220413T184929Z
UID:2711-1650394800-1650403800@thebiocalendar.com
SUMMARY:How to Get an Edge Over Your Competitors to Win the Product Development Race
DESCRIPTION:Over the years\, we have witnessed unprecedented success\, advancement\, and investment in biotech R&D. As a result\, R&D competition is as fierce as it has ever been. But many companies are only focused on their progress of assets and portfolios and that inward-facing diligence typically does not incorporate a rational\, pragmatic\, and unbiased view of the overall competition. Rather\, an extensive overall review increases knowledge about what an organization is up against and informs strategic decisions on how to win. This is the value of competitive intelligence. \nPlease join us to understand how young biotech companies are using competitive intelligence to design smart and meaningful clinical trials\, differentiate their therapy\, and improve the likelihood of regulatory success across different geographical locations. \nMeet Our Speakers: \n \nSarah Boyce\, President & CEO\, Avidity Biosciences \n \nDaniel Corey\, M.D.\, Founder & CSO\, CERo Therapeutics \n \nChris Kreuger\, CBO\, Ventyx Bio \n \nErika Dahl\, Consultant\, Strategy & Program Leadership\, Halloran Consulting Group \n \nAnmol Grover\, Associate Principal Consultant\, Halloran Consulting Group (Moderator) \nThe panel will discuss the following topics: \n\nIdentifying the importance of competitive intelligence and why it’s essential to an organization and their investors\nHow to decide the best timing to gather this insight – when is it too early?\nHow to streamline the most essential competitive intelligence arenas\, such as regulatory precedents\, competitor information\, and clinical operation parameters?\nHow to identify the key competitive intelligence sources?\nHow to maximize all that information and use that for a competitive development strategy to differentiate your organization?\nWhen to conduct competitive intelligence internally vs. externally and how to establish that structure\, support system\, and key objectives?\n\nSponsored by: \n \n*Halloran Consulting Group’s Strategy and Program Leadership group has assisted clients in identifying the unmet need\, the current treatment landscape\, approved and to-be approved therapies\, and interventions in clinical and preclinical stages of development. These insights dovetailed with tailored development strategy\, has helped clients to differentiate their drug from competitors and carve a niche market within the dense treatment landscape. 
URL:https://thebiocalendar.com/event/how-to-get-an-edge-over-your-competitors-to-win-the-product-development-race/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220420
DTEND;VALUE=DATE:20220423
DTSTAMP:20260613T061830
CREATED:20211106T201906Z
LAST-MODIFIED:20211106T201906Z
UID:2371-1650412800-1650671999@thebiocalendar.com
SUMMARY:The Cell & Gene Meeting on the Mediterranean
DESCRIPTION:The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector\, this program features expert-led panels\, extensive one-on-one partnering capabilities\, exclusive networking opportunities\, and 80+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.
URL:https://thebiocalendar.com/event/the-cell-gene-meeting-on-the-mediterranean/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220420T123000
DTEND;TZID=UTC:20220420T133000
DTSTAMP:20260613T061830
CREATED:20220413T185858Z
LAST-MODIFIED:20220413T185858Z
UID:2721-1650457800-1650461400@thebiocalendar.com
SUMMARY:Biotech Market Opportunities Abroad: Partnering with the U.S. Commercial Service in the Bay Area
DESCRIPTION:Join Biocom California and the U.S. Commercial Service of the U.S. Department of Commerce for a live webinar about biotech expansion opportunities in Germany and the U.K. The panel will discuss how the CS can assist Bay Area biotechs with resources\, USG assistance\, and inroads to the German and U.K. markets. Featured speakers from Bay Area-based Gritstone Bio and Invitae will share lessons learned when expanding abroad. Commercial Specialists from Germany and the U.K. will also be present to take questions from members. \nSpeakers: \n\nAndrew Allen\, CEO\, Gritstone Bio\nTony Jones\, CEO\, One Nucleus\nDr. Gregor Kemper\, Senior Manager Medical Biotechnology\, Germany Trade & Invest\nMaria-Elena Rivero\, U.S. Commercial Service\, San Francisco\, Biotech\nVishal Sikri\, President\, Oncology\, Invitae
URL:https://thebiocalendar.com/event/biotech-market-opportunities-abroad-partnering-with-the-u-s-commercial-service-in-the-bay-area/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220421T130000
DTEND;TZID=UTC:20220421T143000
DTSTAMP:20260613T061830
CREATED:20220413T182326Z
LAST-MODIFIED:20220413T182326Z
UID:2707-1650546000-1650551400@thebiocalendar.com
SUMMARY:The Investor Mindset & How to Cater your Pitch in the Current Economy
DESCRIPTION:How does the current economic environment affect the biotech venture investor mindset and outlook? How should you position your company and cater your pitch for success? Join our expert panel for an informative and eye-opening webinar. \nSpeakers:\n—Mike Powell\, Executive Partner\, Omega Funds\n—Shobha Parthasarathi\, Vice President\, Xontogeny\n—Kanad Das\, Investment Director\, Boehringer Ingelheim Venture Fund\n—Ed Saltzman\, Head\, Biotech Strategy\, Lumanity (moderator)
URL:https://thebiocalendar.com/event/the-investor-mindset-how-to-cater-your-pitch-in-the-current-economy/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/04/37eb5188-987a-453a-85b2-99f5d55cbe36.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220421T170000
DTEND;TZID=UTC:20220421T183000
DTSTAMP:20260613T061830
CREATED:20220315T195718Z
LAST-MODIFIED:20220315T195718Z
UID:2659-1650560400-1650565800@thebiocalendar.com
SUMMARY:Cell & Gene Therapies Annual Meeting
DESCRIPTION:Cell & Gene therapies are the latest revolution in medicine manufacturing. Unlike small molecules or traditional biotech products\, these therapies introduce cells and genes into a patient to treat the underlying cause of a disease—they are living medicines! \nWhether you are producing biologic drug substance\, conducting sterile fill-finish operations\, or entering into cell and gene therapy\, this meeting will provide the latest information to help your organization have the knowledge and agility needed to meet the needs of the patients we serve. \nOur esteemed speakers will share their experience and recent advancements on Cell & Gene Therapies\, with insights from clinical trials to manufacturing and commercialization aspects of the drugs of the future. \nJoin this interactive virtual session\, to connect with key players\, learning their latest strategies\, challenges and vision for the future of Cell & Gene Therapies.
URL:https://thebiocalendar.com/event/cell-gene-therapies-annual-meeting-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220427
DTSTAMP:20260613T061830
CREATED:20220415T175953Z
LAST-MODIFIED:20220415T175953Z
UID:2727-1650844800-1651017599@thebiocalendar.com
SUMMARY:Stanford Drug Discovery Symposium (SDDS)
DESCRIPTION:Welcome to 2022 Stanford Drug Discovery Symposium. This symposium provides a valuable and important platform for inspiring interdisciplinary exchange at the forefront of drug research and will support a fantastic networking experience. It provides a great resource for researchers\, pharmaceutical companies\, investment groups\, and those in the wider biomedical community interested in discovering new drugs and improving patient care. We look forward to an exciting two days of talks and discussion. \n\n\n\n\n\n\n\n\n\n— Joseph C. Wu\, MD\, PhD | Director\, Cardiovascular Institute
URL:https://thebiocalendar.com/event/stanford-drug-discovery-symposium-sdds/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260613T061830
CREATED:20211106T202200Z
LAST-MODIFIED:20211106T202200Z
UID:2374-1650931200-1651103999@thebiocalendar.com
SUMMARY:BioTrinity 2022
DESCRIPTION:BioTrinity 2022: Catalysing Growth in the Life Sciences Industry \nBioTrinity is a proven\, must-attend London conference\, that catalyses growth and supports in-person re-engagement across the life sciences industry. \nThe event is attended by an ever-evolving audience of early stage and emerging life sciences R&D Companies\, investors\, large pharma\, and other valued partners throughout the life sciences ecosystem. The conference features a focused\, relevant\, and stimulating programme\, led by great speakers\, who bring their knowledge\, expertise\, and vision to the fore in exciting\, high-quality sessions. \nInteracting with new companies each year is something we believe to be a critical attribute of a successful conference and we work hard to ensure that a substantial and fresh line-up of investable opportunities and collaboration possibilities are showcased.
URL:https://thebiocalendar.com/event/biotrinity-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260613T061830
CREATED:20220319T053531Z
LAST-MODIFIED:20220319T200054Z
UID:2662-1650931200-1651103999@thebiocalendar.com
SUMMARY:Charles River's 6th Annual Viral Safety and Viral Clearance Summit
DESCRIPTION:Join us for a two-day event uniting experts on viral safety and viral clearance taking place at the Hyatt Centric Fisherman’s Wharf in San Francisco\, CA. Gain insight from expert regulatory authorities\, academic researchers\, and industry leaders who are defining the way we evaluate biologics\, vaccines\, and advanced therapeutic medicinal products (ATMPs). Discover new technologies\, learn best practices\, and achieve a solid understanding for designing an efficient manufacturing process.
URL:https://thebiocalendar.com/event/charles-rivers-6th-annual-viral-safety-and-viral-clearance-summit/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2022/03/Viral-Safety-and-Viral-Clearance-Summit-Image.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260613T061830
CREATED:20220411T052608Z
LAST-MODIFIED:20220411T052647Z
UID:2700-1650931200-1651190399@thebiocalendar.com
SUMMARY:WuXi Healthcare Forum 2022
DESCRIPTION:Dear Colleagues and Friends\, \nJoin thousands from around the world virtually this April 26-28 for the complimentary global WuXi Healthcare Forum 2022 as our industry and R&D ecosystem converge to respond to the World Health Organization’s calls for urgent action to address Noncommunicable Diseases (NCD) – with cardiovascular diseases\, cancer\, and neurological disorders as the top challenges – which are collectively responsible for almost 70% of all deaths worldwide. \nA vital opportunity to take actions on topics that matter – \n• Rising to the Challenge: Why are the challenges facing our ecosystem so urgent? What’s holding us back from making new progress? How do we continue to break through barriers? AstraZeneca’s BioPharmaceuticals R&D Chief Sir Menelas Pangalos\, Director of NINDS/NIH\, Walter Koroshetz\, Chief Science & Medical Officer of American Heart Association\, Mariell Jessup\, CVCT Forum Chair\, Faiez Zannad\, Chief Patient Officer of American Cancer Society\, Arif Kamal\, CEO-Partner of Flagship Pioneering\, Stephen Hahn\, and J&J’s External Innovation Chief\, William Hait\, will share their perspectives and vision for the future. \n• Moving the Needle in Neurological Disorders: A dynamic VC roundtable featuring Laurence Barker of The Dementia Discovery Fund\, Philip Scheltens of the Dementia Fund at EQT Life Sciences\, Christina Isacson of Lightstone Ventures\, and Rana Al-Hallaq of Pfizer Ventures. \n• Spotlight on Parkinson’s Disease: To highlight Parkinson’s Disease Awareness Month this April\, we will showcase the unique challenges and opportunities facing the development of new therapeutics for PD’s with a dialogue between Todd Sherer of the Michael J. Fox Foundation and Andrew Siderowf of the University of Pennsylvania School of Medicine. \n• Revitalizing Cardiovascular R&D: What are the rate-limiting steps of CVD R&D? How can we move the dial on drug discovery & development towards finding a cure? Simone Fishburn\, Chief Editor of BioCentury will lead a C-suite roundtable with Sekar Kathiresan of Verve Therapeutics\, Claudia Ulbrich of Cardior Pharmaceuticals\, Christopher de Souza of Broadview Ventures\, and Michael Mendelsohn of Cardurion Pharmaceuticals. \n• Conquering the Next Frontiers in Cancer Therapies: How can we tackle difficult cancers? How do we breach the heterogeneity issue in cancer therapeutic development? Are we delivering on the promise of precision medicine for cancers? These and many more questions will be debated among a leading expert panel\, featuring Lewis Williams of Walking Fish Therapeutics\, Adam Friedman of Scorpion Therapeutics\, Luba Greenwood of Kojin Therapeutics\, Rajesh Chopra of Apple Tree Partners\, and KT Moortgat of Droia Ventures. \n• And more on new modalities\, new targets and new enabling platforms… \nComplimentary and open to the global healthcare innovation ecosystem\, this 3-day program will premiere via Zoom from 8 AM – 11 AM PDT (11 AM – 2 PM EDT) daily on April 26-28. \nClick HERE for our speaker bios and program agenda. \nGlobal challenges require global solutions and global collaborations. We hope you will join us for this year’s dynamic discussions. \nBest regards\, \nWuXi Healthcare Forum Committee
URL:https://thebiocalendar.com/event/wuxi-healthcare-forum-2022/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220426T100000
DTEND;TZID=UTC:20220426T110000
DTSTAMP:20260613T061830
CREATED:20220415T180700Z
LAST-MODIFIED:20220415T180700Z
UID:2728-1650967200-1650970800@thebiocalendar.com
SUMMARY:Expediting Access to Novel/Medicinal Products in the US and EU
DESCRIPTION:Regulatory Pathways Available to Speed Development and Approval\n \nVeristat and TOPRA will be hosting a webinar on the topic of: \nExpediting Access to Novel/Medicinal Products\nin the United States and Europe\nTuesday\, April 26\, 2022\n10:00 AM – 11:00 AM EDT (15:00 -16:00 BST) \n\nWhat  You Will Learn\nBringing novel medicinal products to market is a long\, complex\, and expensive process which requires drug developers to balance the need for rigorous testing with the goal of getting medicines quickly to patients who need them. To this end\, both US and European regulatory agencies have developed expedited pathways to accelerate the approval process for therapies that treat serious conditions and unmet medical needs.   \nVeristat Regulatory experts will discuss how developers of such therapies can utilize some or multiple programs/pathways to accelerate approval in the US and Europe. This webcast will highlight the requirements\, benefits\, and procedures for following US pathways: Accelerated Approval\, Breakthrough Therapy Designation\, Fast Track\, and Priority Review Designation. Then we will examine the similarities and differences to the EU pathways: Accelerated Assessment\, Conditional Marketing Application (CMA)\, and Priority Medicines Scheme (PRIME). The discussion will culminate with real-world examples and success stories.  \nOur experts will share their experience\, successes\, and lessons learned on how to: \n\nUnderstand when and how to apply for the following expedited pathways with FDA and European Regulatory Authorities:\n\n\n Breakthrough Therapy (BT)\n Fast Track (FT)\n Priority Review\n Accelerated Approval\n Accelerated Assessment\n Conditional Marketing Authorization (CMA)\n PRIME \n\n\n Consider real-world examples of increased efficiency with submitting pathways requests with FDA and EMA independently and simultaneously
URL:https://thebiocalendar.com/event/expediting-access-to-novel-medicinal-products-in-the-us-and-eu/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220427T140000
DTEND;TZID=UTC:20220427T150000
DTSTAMP:20260613T061830
CREATED:20220425T214108Z
LAST-MODIFIED:20220425T214110Z
UID:2744-1651068000-1651071600@thebiocalendar.com
SUMMARY:Halloran Speaker Series | The Future of RBQM and Customized Key Risk Indicator Libraries: How Small Companies Can Take Big Steps to Reduce Risk and Trial Oversight
DESCRIPTION:Identifying the key risks to be monitored in a clinical study is critical for a successful implementation of a Risk-Based Quality Management process (RBQM)\, and even more\, to the overall success of the clinical trial. Identifying the right Key Risk Indicators (KRIs) is also of utmost importance because they are the risk indicators that enable clinical study teams to proactively make informed decisions along the way. To put it simply\, a study team needs the right KRIs to actively monitor the trial’s risks. \nWe’ve witnessed many small biopharma companies wonder if there are different ways to identify and manage KRIs for their trial\, particularly\, because many face the challenge of not having enough data to inform KRI selections from the onset. Some companies just don’t have that data and insight\, so they often rely on a KRI library from their vendors. \nAs we zoom out from those observations\, we want to share our insights with you on the future of RBQM that will be helpful especially to smaller companies\, particularly around the following questions: \nIf you don’t have enough data to inform decisions on KRIs\, where do you start?\nHow do you implement a risk-based quality management process to inform KRIs?\nShould companies have a library of KRIs to utilize from the onset?\nWhat does it look like to overdo it vs. underdo it and why does this viewpoint matter?\nHow should companies partner with their vendors on KRIs?\nHow should you develop KRIs if you outsource your studies to CROs?\nWhen should you start developing KRIs and your RBQM processes?\nWhat does the future of customized risk management look like? \nWe invite you to this conversation on Thursday\, April 27th from 2-3 pm ET on “The Future of RBQM and Customized Key Risk Indicator Libraries How Small Companies Can Take Big Steps to Reduce Risk and Provide Trial Oversight” led by Sheila Gwizdak\, VP of Quality at Halloran Consulting Group\, and members of the Organizational Quality Solutions and Clinical teams during our Halloran-hosted Speaker Series.
URL:https://thebiocalendar.com/event/halloran-speaker-series-the-future-of-rbqm-and-customized-key-risk-indicator-libraries-how-small-companies-can-take-big-steps-to-reduce-risk-and-trial-oversight/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/04/Speaker-Series-4.27.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220427T160000
DTEND;TZID=UTC:20220427T190000
DTSTAMP:20260613T061830
CREATED:20220404T095332Z
LAST-MODIFIED:20220517T072215Z
UID:2680-1651075200-1651086000@thebiocalendar.com
SUMMARY:Virtual BioXchange April 27
DESCRIPTION:Miss being able to network with colleagues in the life science industry? We have you covered with the best virtual networking experience through Grapevine Network’s networking platform. Connect with life science colleagues from all over the world. \nBioXchange has gone virtual to allow the best online opportunity to interact with individuals from throughout the life science industry. The event will be hosted on Grapevine Network’s platform which provides an amazing experience that allows attendees the freedom to navigate between different group discussions within an interactive chatroom environment. The platform provides the closest experience to a live networking experience. \nParticipants are welcome to join the event at any point of time. The event is subject to run later than the posted end time as the room will stay open as long as people are actively engaged within the chat room. \n***Event is expected to sell out and NOT ALL RVSPS ARE GUARANTEED ENTRY into the event due to the limited attendee capacity offered on the platform.
URL:https://thebiocalendar.com/event/virtual-bioxchange-7/
ATTACH;FMTTYPE=image/gif:https://thebiocalendar.com/wp-content/uploads/2022/04/Purple-Zodiac-Sign-Animated-Presentation-13-1.gif
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220428T073000
DTEND;TZID=UTC:20220429T160000
DTSTAMP:20260613T061830
CREATED:20211228T232305Z
LAST-MODIFIED:20220415T182712Z
UID:2471-1651131000-1651248000@thebiocalendar.com
SUMMARY:Patients as Partners in Clinical Research
DESCRIPTION:The 9th annual Patients as Partners in Clinical Research is a 2-day festival of real-world examples from patients\, pharma and FDA on how patient involvement is implemented to drive greater efficiencies in clinical research. Each session demonstrates the what\, where\, when and how and measures the impact of those initiatives. \nKey Topic Areas:\n– Applying Patient Engagement Initiatives and Demonstrating Impact\n– Patient Input to Help R&D Obtain Better Outcomes from Clinical Research\n– FDA Guidance Updates and New Agency Efforts\n– Returning Data to Patients\n– Advancing Hybrid/Decentralized Clinical Trial Initiatives\n– Community Engagement & Building Trust to Ensure Diversity\, Equity and Inclusion in Clinical Research\n– Operationalizing Patient Engagement From Research Through to Commercialization\n– New Tools for Patient Experience Mapping\, Optimizing Digital Inclusion and Increasing Diversity and Inclusion in Clinical Trials\n– Collaborative Efforts for Reducing the Burden at the Site Level to Better Serve Patients \nPLUS….Interactive Sessions Including:\n– Hackathon on Patient-Centered Clinical Trial Solutions\n– Mapping Hybrid/DCT Opportunities in Medicines Development\n– Birds of a Feather Roundtable Discussions \nLearn more at www.patientsaspartners.org
URL:https://thebiocalendar.com/event/patients-as-partners-in-clinical-research/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2021/12/PatientsasPartners_Bio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220428T110000
DTEND;TZID=UTC:20220428T130000
DTSTAMP:20260613T061830
CREATED:20220415T181044Z
LAST-MODIFIED:20220415T181055Z
UID:2729-1651143600-1651150800@thebiocalendar.com
SUMMARY:Paving the Path to IPO: How to Build Compliant Financial Systems and Processes
DESCRIPTION:Whether you are a fast-growing biotech company or are currently public and looking for SOX compliance\, this webinar will cover how to set up scalable and compliant financial processes. \nGoing public is an exciting and significant milestone for any high-growth company. However\, some IPOs are delayed or even fail\, due to a lack of thorough planning. It’s a complicated process with lots of room for error and risks. \nPrior to going public\, your business must establish secure financial controls to demonstrate responsible financial stewardship and protect the shareholder. This includes supplier due diligence\, accurate record-keeping\, and employee spending thresholds. In addition to financial controls\, extreme growth can often lead to AP bottlenecks. \nAttend this webinar to hear real-life experiences and best practices on how to reduce risk\, build trust\, and increase transparency for decision-making\, by laying the right infrastructure and financial systems for sustainable\, long-term growth. \nKey Learning Objectives: \n\nBuilding scalable Business Spend Management (BSM) processes\nWhat the IPO process looks like and how you can best prepare\nHow to work with third-party auditors\nSOX compliance best practices\nRisk management\n\nWho Should Attend: \n\nFinance and Accounting Professionals\, Operations Professionals\, and IT Professionals
URL:https://thebiocalendar.com/event/paving-the-path-to-ipo-how-to-build-compliant-financial-systems-and-processes/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220428T160000
DTEND;TZID=UTC:20220428T183000
DTSTAMP:20260613T061830
CREATED:20220425T191510Z
LAST-MODIFIED:20220517T235559Z
UID:2741-1651161600-1651170600@thebiocalendar.com
SUMMARY:SoCalBio Networking Forum
DESCRIPTION:Incubator vs Accelerator: What is more beneficial to a startup entrepreneurs\nJoin us to learn about and network with incubators in the Greater Los Angeles Metro Area that are fueling the growth of biotech and medtech entrepreneurial activities. The event will feature the following incubators and accelerators: \n\nLA Biospace (East Los Angeles)\nMagnify at UCLA (Westwood)\nNXT Biomedical (Irvine)\nPasadena Bio Collaborative (Pasadena)\nMurrieta Genomics (Murrieta)\nVentura BioCenter (Thousand Oaks)\nBioLabs at Lundquist Inst. (Torrance)\nULP at UCI (Irvine)\nOak Crest Institute (Monrovia)\n\n\n\nAgenda\n1:00 PM – 1:15 PM SoCalBio Introduction \n1:15 PM – 2:15 PM Incubator Panel \n2:15 PM – 3:15 PM Accelerators Panel \n3:15 PM – 3:25 PM Business Support Panel \nQ&A until the End of Showcase
URL:https://thebiocalendar.com/event/socalbio-networking-forum-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220502
DTEND;VALUE=DATE:20220505
DTSTAMP:20260613T061830
CREATED:20220304T204314Z
LAST-MODIFIED:20220304T204314Z
UID:2639-1651449600-1651708799@thebiocalendar.com
SUMMARY:2022 Texas Life Science CEO Summit
DESCRIPTION:The CEO Summit is THE must attend event for Life Science CEOs in the state of Texas. This is an intimate and exclusive two-day event with an agenda hand crafted by CEOs. Most importantly\, this program provides a platform for CEOs from each region of the state to come together to network and exchange ideas in an informal setting.  Revised agenda to follow. \n**Please note that registration for this event is limited to CEOs of Texas life science companies.**
URL:https://thebiocalendar.com/event/2022-texas-life-science-ceo-summit/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220502
DTEND;VALUE=DATE:20220507
DTSTAMP:20260613T061830
CREATED:20220411T052505Z
LAST-MODIFIED:20220415T182609Z
UID:2699-1651449600-1651881599@thebiocalendar.com
SUMMARY:PEGS Boston
DESCRIPTION:PEGS Boston Returns In-Person in 2022 \n\n\nNow in its eighteenth year\, the PEGS Boston Summit is recognized as the leading international meeting place for the biotherapeutics community. PEGS Boston highlights a wide spectrum of biologic drug development with in-depth presentations on protein and antibody engineering\, immunotherapy\, oncology\, expression\, analytical\, immunogenicity\, and more. \nAs we navigate the new realities of conferences and gatherings\, you can count on CHI’s commitment to deliver quality content and facilitated networking opportunities to help achieve your research goals. Our new hybrid event model gives you the option to experience the summit safely in-person or securely online. \nJoin your peers and colleagues from around the world at PEGS Boston Summit to share insights\, case studies\, cutting-edge research\, and form collaborations to advance biotherapeutics development.
URL:https://thebiocalendar.com/event/pegs-boston/
CATEGORIES:Featured
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220503T193000
DTEND;TZID=UTC:20220503T213000
DTSTAMP:20260613T061830
CREATED:20220413T185751Z
LAST-MODIFIED:20220413T185751Z
UID:2720-1651606200-1651613400@thebiocalendar.com
SUMMARY:Let's Taco 'Bout Networking: An Evening Reception with Lonza
DESCRIPTION:You’re Invited to Taco Tuesday \nBiocom California and Lonza invite you to join us on Tuesday\, May 3 for a Taco Tuesday networking reception at Farmer & The Seahorse to connect in a causal environment. \nThe evening is an opportunity to discover and discuss the important relationship among CDMOs and emerging biotech companies working together to develop lifesaving drug products while enjoying mouthwatering tacos\, live music and more. \nWho Should Attend: \nWe welcome all C-suite officers in pharmaceutical/biotech\, as well as company executives focusing on product development\, CMC/manufacturing\, outsourcing\, technical operations\, and consultants to join us for the networking event. \n*Please note: This event is only open to industry companies and closed to any service provider and/or direct competitor of Lonza. Biocom California reserves the right to cancel and refund the registration if it does not meet the criteria listed above.
URL:https://thebiocalendar.com/event/lets-taco-bout-networking-an-evening-reception-with-lonza/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220504
DTEND;VALUE=DATE:20220508
DTSTAMP:20260613T061830
CREATED:20211106T202332Z
LAST-MODIFIED:20211106T202332Z
UID:2375-1651622400-1651967999@thebiocalendar.com
SUMMARY:2022 ASPHO Conference
DESCRIPTION:Be a part of the 2022 ASPHO Conference\, the premier education and networking event for pediatric hematology/oncology professionals. \nGain critical knowledge from the breadth of education on treatment and research discoveries shared at the 2022 ASPHO Conference.\nAt this time\, the conference will occur in-person\, and we look forward to providing you with the opportunity to reconnect with colleagues and friends in Pittsburgh. ASPHO is monitoring the state of the COVID-19 pandemic and implementing all precautions necessary to ensure a safe in-person meeting experience. \nImportant Dates\n\nThe Call for Papers and Posters is open November 4\, 2021\, through January 13\, 2022\, at 3 pm CT. The ASPHO Conference Planning Committee invites paper and poster abstract submissions\, in particular original basic\, clinical and social-science abstracts that relate to the pediatric hematology/oncology field. All accepted abstracts will be published in the Pediatric Blood & Cancer Journal.\n\n\n“We are thrilled to welcome ASPHO back to our great city of Pittsburgh! I encourage PHO friends and colleagues to come and enjoy all that this beautiful city has to offer! The landscape is other-worldly with gorgeous hills\, rivers and bridges and lots of great opportunities for walking\, hiking and biking. Make sure to visit the inspiring campuses of Carnegie Mellon University and University of Pittsburgh\, including the iconic PITT Cathedral of Learning. And take a ride on the incline to the top of Mount Washington – ranked #6 for best skyline view in the U.S.!” – Linda M. McAllister-Lucas\, MD PhD \nJoin alongside colleagues at #ASPHO2022 for in-person learning\, networking\, and professional development in Pittsburgh\, including:\n\nOriginal research presentations\nSessions led by experts and thought leaders in pediatric hematology/oncology\nA diverse schedule covering the breadth of the field with educational sessions\, research paper presentations\, and posters\nConvenient Maintenance of Certification and CME opportunities\nSpecial Interest Group workshops\nGenius Bars\, Speed Mentoring\, and Early Career RoundTable\n\nPrograms benefit professionals from throughout the field:\n\nSubspecialist investigators and practitioners from every sector of pediatric hematology/oncology\nHospitalists\, physician assistants\, advanced nurse practitioners\, other advanced practice providers\, and allied healthcare professionals\nEarly\, mid-and late-career professionals from the U.S. and abroad\nMedical residents and students wanting advanced subspecialty knowledge
URL:https://thebiocalendar.com/event/2022-aspho-conference/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220504T110000
DTEND;TZID=UTC:20220504T180000
DTSTAMP:20260613T061830
CREATED:20220415T174616Z
LAST-MODIFIED:20220415T174616Z
UID:2723-1651662000-1651687200@thebiocalendar.com
SUMMARY:Leading from the Boardroom: Navigating the Life Sciences Boardroom
DESCRIPTION:Join directors and C-suite executives in the life sciences industry as the NACD Research Triangle Chapter provides a full day of educational programming and networking. The agenda will focus on key issues being addressed in the life science boardroom\, including an assessment of how the nation’s biotech hubs are emerging from the Covid-19 pandemic. The program also features sessions on drivers of innovation\, fundraising\, strategic partnerships and the maturity curve of the life sciences board. Ongoing challenges in supply chain\, human capital management and DE&I will be addressed throughout each discussion. Facilitated peer-to-peer discussion groups are scheduled during the “Birds of a Feather” lunch\, and the day wraps up with a social hour.
URL:https://thebiocalendar.com/event/leading-from-the-boardroom-navigating-the-life-sciences-boardroom/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220505T160000
DTEND;TZID=America/New_York:20220505T183000
DTSTAMP:20260613T061830
CREATED:20220331T001715Z
LAST-MODIFIED:20220505T021122Z
UID:2672-1651766400-1651775400@thebiocalendar.com
SUMMARY:BVS’ Biotech Community Cinco de Mayo Celebration at Tech Square
DESCRIPTION:We are very excited to announce our outdoor Biotech Cinco de Mayo Community Event at the Tech Square Courtyard\,  Kendall Square\, 400 Technology Square\, Cambridge\, MA\, 02139\nAll the biotech tenants at 100-700 Technology Square and other companies in the Cambridge vicinity will be invited to attend this event.\nThe event is being promoted as a special Biotech Community Event sponsored by the best scientific suppliers in the industry along with it being a wonderful way for scientists and science vendors to network in a relaxed evening venue.\nThe event will be a combination of vendor exhibits\, food\, beer & wine. We will have extra special raffle prizes and expect an excellent turnout.
URL:https://thebiocalendar.com/event/bvs-biotech-community-cinco-de-mayo-celebration-at-tech-square/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/03/BVS-Biotech-Event-Flyer-5-5-22-9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220505T180000
DTEND;TZID=UTC:20220505T210000
DTSTAMP:20260613T061830
CREATED:20220404T215859Z
LAST-MODIFIED:20220404T215859Z
UID:2684-1651773600-1651784400@thebiocalendar.com
SUMMARY:4th Annual The Dan Diaz Biotech Breakfast Club ALS Fundraiser
DESCRIPTION:In support of the ALS Association\, Greater Philadelphia Chapter\, The Dan Diaz Biotech Breakfast Club with partnerships with Women in Bio\, GTS Scientific\, The Bracken Group\, and the PA Biotech Center of Bucks County will host its 4th annual fundraiser. Our goal is to raise funds and awareness for ALS research.
URL:https://thebiocalendar.com/event/4th-annual-the-dan-diaz-biotech-breakfast-club-als-fundraiser/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220512
DTSTAMP:20260613T061830
CREATED:20211103T055709Z
LAST-MODIFIED:20220103T195053Z
UID:2347-1652140800-1652313599@thebiocalendar.com
SUMMARY:LSX World Congress
DESCRIPTION:The 8th LSX World Congress gathers the founders and CEOs of innovative start-ups through to healthcare giants\, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future. \nThe biotech\, healthtech and medtech industry’s c-suite will be joined by the sector’s most active investors\, pharma and health technology BD&L teams\, R&D leaders\, KOLs and top tier service companies who are driving the sector forward. \nThe Congress helps answer the question; what’s next and how do we get there? \nLSX is committed to keeping everyone attending the Congress as safe as possible. Learn more about our safety protocols here.
URL:https://thebiocalendar.com/event/lsx-world-congress/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220510T163000
DTEND;TZID=America/Los_Angeles:20220510T190000
DTSTAMP:20260613T061830
CREATED:20220331T005044Z
LAST-MODIFIED:20220502T070732Z
UID:2674-1652200200-1652209200@thebiocalendar.com
SUMMARY:BVS’ Biotech Community Event at SOVA Science District
DESCRIPTION:We are very excited to announce our outdoor Biotech Community Event at SOVA Science District\, 11545 Sorrento Valley Rd\, San Diego\, CA\, 92121\nOur last event was a HUGE success with 250 high-quality people registering from over 100+ companies/institutes & we will once again be inviting the entire So CA Life Science Community to attend.\nThe event is being promoted as a special Biotech Community Event sponsored by the best scientific suppliers in the industry along with it being a wonderful way for scientists and science vendors to network in a relaxed evening venue.\nThe event will be a combination of vendor exhibits\, tacos and beer. We will have extra special raffle prizes and expect an excellent turnout.
URL:https://thebiocalendar.com/event/bvs-biotech-community-event-at-sova-science-district/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2022/03/BVS-Biotech-Event-Flyer-5-10-22-7.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220516T083000
DTEND;TZID=UTC:20220517T120000
DTSTAMP:20260613T061830
CREATED:20220302T185001Z
LAST-MODIFIED:20220302T185001Z
UID:2635-1652689800-1652788800@thebiocalendar.com
SUMMARY:BioBriefing
DESCRIPTION:BioBriefing is a comprehensive\, virtual two-half-day course providing you with an overview of the development of biopharmaceuticals.  The course will start with foundational basics and give a detailed overview of the entire process from discovery to commercialization.  As an attendee\, you will learn a bit of the science behind biotech products\, the clinical research process\, regulatory filings\, and scale-up for manufacturing.  Different types of products such as biologic drugs\, biosimilars\, personalized medicine\, stem cell\, and regenerative medicine will be outlined.
URL:https://thebiocalendar.com/event/biobriefing/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220517T190000
DTEND;TZID=UTC:20220517T210000
DTSTAMP:20260613T061830
CREATED:20220413T185601Z
LAST-MODIFIED:20220413T185700Z
UID:2718-1652814000-1652821200@thebiocalendar.com
SUMMARY:The Future of Immune Cell Therapy
DESCRIPTION:Join the Cell and Gene Therapy Committee for a Bay Area discussion on the future of immune cell therapy. Panelists will share their experience and insights on the current state of the field and strategies for how to move it forward. Topics will include: \n\n“Next-gen” autologous or Allogeneic?\nWhich cell types seem to hold the greatest promise (CAR-T\, TCR\, CAR-NK\, other?)\nAre solid tumor treatments coming soon?\nWhat are the clinical and CMC challenges?\n\nThe Cell and Gene Therapy Committee is co-chaired by Jens Vogel\, SVP and Global Head of Biotech at Bayer\, and Jeff Bluestone\, CEO and President at Sonoma Biotherapeutics\, and they will co-moderate the conversation. Audience members are invited to participate in this interactive conversation. \nThis meeting is reserved for industry companies engaged in cell and gene therapy research\, development and commercialization. Service providers will be admitted on approval by the Committee chairs.
URL:https://thebiocalendar.com/event/2718/
END:VEVENT
END:VCALENDAR